Alagille Syndrome Market Analysis
Market Research Future predicts a considerable growth of the global alagille syndrome market, expected to register a notable CAGR over the forecast period of 2018-2023.
Liver damage resulting due to abnormalities in the bile duct is called alagille syndrome. It is a genetic disorder.
The surge in occurrence of genetic disorders, the increase in number of cases of alagille syndrome, and the increase in healthcare expenditure are factors that are anticipated to fuel the global alagille market growth.
However, the lack of awareness about alagille syndrome can impede the expansion of its market.
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/6324
Alagille Syndrome Market Segmental Overview
The alagille syndrome market study has been segmented based on symptom, diagnosis, end-user, and treatment.
Based on the symptom, the alagille syndrome market has been segmented into neurologic problems, liver problems, nutrition problems, heart problems, distinctive facial features, and others.
Based on the treatment, the alagille syndrome market has been segmented into kidney surgery, liver transplantation, biliary diversion procedures, heart surgery, medication, vitamin supplements, and others. The anti-histamine segment has been narrowed down on the basis of hydroxyzine and others. The medication segment has been further classified into cholestyramine, naltrexone, ursodeoxycholic acid, anti-histamine, and rifampin.
Based on the diagnosis, the alagille syndrome market has been segmented into prenatal DNA testing, urinalysis, cardiology exam, X-ray imaging, slit-lamp exam, blood test, liver biopsy, genetic testing, and others.
Based on the end-user, the alagille syndrome market has been segmented into diagnostic centers, hospitals and clinics, and others.
Alagille Syndrome Market Regional Study
The geographic study of the alagille syndrome market gives a comprehensive understanding of its demographic progress. By region, the alagille syndrome market forecast has been segmented into North America, South America, Asia Pacific, Europe, and the Middle East Asia and Africa.
The rise in prevalence of rare genetic disorder and the growing awareness of such disorders among people, backed by enhanced treatment owing to technical developments, in North and South America, are identified as the regional market drivers. Hike in disposable income and firm medical infrastructure are other factors bolstering the regional alagille syndrome market expansion.
MRFR forecasts that the global alagille syndrome market in Europe, after North America, is expected to hold the second largest market share over the assessment period. The availability of funds for research and developmental activities, the increase in prevalence of liver disorders and the surge in healthcare expenditure are factors contributing to the European alagille syndrome market growth.
The Asia Pacific alagille syndrome market is envisaged to garner a substantial CAGR over the evaluation period. The market in APAC is expected to grow at a rapid pace. The existence of large patient pool, the presence of emerging economies, and the increase in funding for developments of the healthcare industry are expected to impel the market growth.
The Middle East Asia and Africa is the region spotted to hold the least market share. However, growing initiatives taken by the government to create a better healthcare space can boost the regional alagille syndrome market growth.
Alagille Syndrome Market Key Players
Significant companies mentioned by MRFR are Novartis AG, Pfizer, Inc., GlaxoSmithKline plc, Merck & Co., Inc, Allergan Plc, Lannett, Albireo Pharma, Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., AstraZeneca PLC, Shire, and Sanofi AG.
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/alagille-syndrome-market-6324
Alagille Syndrome Industry News
June 2019: Albireo Pharma, announced that Phase 2 study report of Odevixibat (A4250), in the European Society for Paediatric G Alagille syndrome gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting in Glasgow, Scotland. Odevixibat is a highly potent selective inhibitor of the ileal bile acid transporter (IBAT) that aids in alagille syndrome management.